FORE Awards New Grant to Address Impact of Post-COVID Medicaid Policy Changes on Access to Treatment for Opioid Use Disorder
“Medicaid is the single largest payer for opioid use disorder treatment and a lifeline for people who are often at the highest risk of overdose,” said Karen A. Scott, MD, MPH., president of FORE.
- “Medicaid is the single largest payer for opioid use disorder treatment and a lifeline for people who are often at the highest risk of overdose,” said Karen A. Scott, MD, MPH., president of FORE.
- This latest grant builds on previous support RAND received from FORE for projects to understand the impact of policy changes for prescribing and accessing buprenorphine treatment during COVID-19.
- FORE was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nation’s opioid crisis.
- FORE’s mission is to support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid use disorder, their families, and their communities.